SCHEMBL2935136

SCHEMBL2935136

O=C(O)c1ccc(Nc2cncc(-c3cc4ccccc4[nH]3)n2)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL6 P41182 1/20 0.43
BCOR Q6W2J9 1/20 0.43
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
ITK Q08881 1/20 0.40
CCNA2 P20248 2/20 0.40
CDK2 P24941 2/20 0.40
TTK P33981 2/20 0.40
CSNK2A2 P19784 2/20 0.39
CSNK2A1 P68400 2/20 0.39
AURKA O14965 3/20 0.38
PIM3 Q86V86 3/20 0.38
LDHA P00338 1/20 0.38
LDHB P07195 1/20 0.38
CSNK2B P67870 1/20 0.38
KDR P35968 1/20 0.38
ESR1 P03372 1/20 0.38
PYGL P06737 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2928690 0.87 AURKA (0.47) BCL6BCORCCNA2CDK2TTK
SCHEMBL2932841 0.85 PIM3 (0.48) CASP3SENP8SENP7SENP6CCNA2
SCHEMBL2927739 0.84 KDR (0.51) CCNA2CDK2TTKKDR
SCHEMBL2927043 0.82 HCAR3 (0.48) CASP3SENP8SENP7SENP6ITK
Trifluoroacetic Acid SCHEMBL2932757 0.81 KDR (0.46) CCNA2CDK2TTKKDR
SCHEMBL2928708 0.80 BRAF (0.39) ITKCDK2KDR
SCHEMBL2927770 0.77 CDK2 (0.47) CCNA2CDK2TTKKDR
SCHEMBL2934019 0.77 BRAF (0.47) ITK
SCHEMBL2927502 0.76 PIM3 (0.51) BCL6BCORAURKAPIM3LDHA
SCHEMBL2933640 0.76 CDK2 (0.48) BCL6BCORCDK2CSNK2A2CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044051-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB PUBL (SE) 2010-01-27 EP disclosed
EP-2044051-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (publ) (SE) 2009-04-08 EP disclosed
US-20080039450-A1 Compounds BIOVITRUM AB (PUBL.) (SE) 2008-02-14 US disclosed
WO-2007147874-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS BIOVITRUM AB (PUBL) (SE) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039450-A1 Compounds NEK2, CSNK2A3, CSNK2A1 BCL6 4594/4885BCOR 3225/4885CASP3 3930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.